Discontinued — last reported Q2 '23
EMCOR Group Acquisitions decreased by 64.1% to $43.67M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.9%, from $850.64M to $43.67M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 71.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.52M | $57.81M | $4.58M | $2.91M | $23.70M | $64.46M | $7.58M | $11.83M | $10.55M | $67.36M | $6.75M | $100.00K | $173.17M | $15.94M | $38.97M | $850.64M | $36.59M | $13.26M | $121.61M | $43.67M |
| QoQ Change | — | +83.4% | -92.1% | -36.4% | +713.3% | +172.0% | -88.2% | +56.2% | -10.9% | +538.5% | -90.0% | -98.5% | >999% | -90.8% | +144.4% | >999% | -95.7% | -63.8% | +817.2% | -64.1% |
| YoY Change | — | — | — | — | -24.8% | +11.5% | +65.4% | +306.1% | -55.5% | +4.5% | -10.9% | -99.2% | >999% | -76.3% | +477.3% | >999% | -78.9% | -16.8% | +212.1% | -94.9% |